<DOC>
	<DOCNO>NCT01631214</DOCNO>
	<brief_summary>The purpose study determine treatment effective preventing fracture woman postmenopausal osteoporosis</brief_summary>
	<brief_title>Study Determine Efficacy Safety Romosozumab Treatment Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Postmenopausal woman osteoporosis high risk fracture define : 1. hip BMD Tscore ≤2.5 SD vertebral fracture 2. hip BMD Tscore ≤2.0 SD recent hip fracture two vertebral fracture . History metabolic bone disease ( except osteoporosis ) Use agent affect bone metabolism Vitamin D insufficiency History solid organ bone marrow transplant Hyper hypocalcemia Hyper hypothyroidism Hyper hypoparathyroidism Possible sign intolerance Alendronate</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis , Osteoporosis-postmenopausal , Bone Diseases-Metabolic , Bone Diseases , Musculoskeletal Diseases</keyword>
</DOC>